AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3593895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3593895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily) in elderly subjects
Number of subjects: 17
Study 31682137 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprexis adjunctively to care-as-usual (n = 509)
Number of subjects: 1013
Study 31682137 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (n = 504)
Number of subjects: 1013
Study 29300973 — intervention group
Group type: EXPERIMENTAL
Intervention: SCST plus in vivo community‐based training
Number of subjects: 139
Study 29300973 — intervention group
Group type: EXPERIMENTAL
Intervention: SCST plus clinic‐based training
Number of subjects: 139
Study 29300973 — intervention group
Group type: COMPARATOR
Intervention: Illness management control condition
Number of subjects: 139
Study 27390049 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of pidotimod
Number of subjects: 20
Study 27390049 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic modeling method
Number of subjects: 20
Study 24899528 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygienic-dietary recommendations (Mediterranean diet and exercise)
Number of subjects: 0
Study 24899528 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22671310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser therapy
Number of subjects: 31
Study 21389909 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 21389909 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable DES platforms
Number of subjects: 0
Study 18401024 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 139
Study 18401024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 15790616 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 4892
Study 15790616 — intervention group
Group type: COMPARATOR
Intervention: Statin untreated group
Number of subjects: 4892
Study 12920692 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study 12920692 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0
Study 12920692 — intervention group
Group type: COMPARATOR
Intervention: TNF inhibitors (general)
Number of subjects: 0
Study 10571597 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg twice daily (n=319)
Number of subjects: 623
Study 10571597 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg twice daily
Number of subjects: 623
Study 10571597 — intervention group
Group type: COMPARATOR
Intervention: Mebeverine 135 mg three times daily (n=304)
Number of subjects: 623
Study 8916244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (outpatient setting)
Number of subjects: 38
Study 8916244 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-and-recovery model (inpatient setting)
Number of subjects: 38
Study 8916244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral model (inpatient setting)
Number of subjects: 38
Study 8916244 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 38
Study 1841578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin (0.2 mg) applied once during trabeculectomy
Number of subjects: 32
Study 1841578 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (5 mg) injected subconjunctivally 10 times in 2 weeks after surgery
Number of subjects: 32
Study 1841578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin group
Number of subjects: 32
Study 1841578 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil group
Number of subjects: 32
Study 6357204 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgotein (2 mg)
Number of subjects: 0
Study 6357204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30774323 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 35
Study 30774323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 30020256 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival provocation test (CPT) performed 4 weeks after initiating AIT
Number of subjects: 0
Study 30020256 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival provocation test (CPT) performed prior to starting AIT
Number of subjects: 0
Study 30020256 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival provocation test (CPT)
Number of subjects: 0
Study 26521057 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient involvement in the design of the clinical trial
Number of subjects: 30
Study 26521057 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 30
Study 26004592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 108
Study 26004592 — intervention group
Group type: COMPARATOR
Intervention: Fesoterodine 8 mg
Number of subjects: 108
Study 22098585 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 9
Study 20541709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure recovery adjustment of AVA
Number of subjects: 1563
Study 20541709 — intervention group
Group type: COMPARATOR
Intervention: Unadjusted AVAI
Number of subjects: 1563
Study 20541709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure recovery and ELI calculated at different aortic root levels
Number of subjects: 1563
Study 20541709 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of AVAI and ELI
Number of subjects: 1563
Study 18824917 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (30 ppm) + glucocorticoids (2 mg/kg)
Number of subjects: 15
Study 18824917 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrogen) + glucocorticoids (2 mg/kg)
Number of subjects: 15
Study 15652879 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (2,000 stimulations per day at 90% of motor threshold) over the left temporoparietal cortex for 5 days
Number of subjects: 10
Study 15652879 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS for 5 days
Number of subjects: 10
Study 11803256 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ammonium lactate in W/O vehicle
Number of subjects: 20
Study 11803256 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% urea in W/O vehicle
Number of subjects: 20
Study 11803256 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% ammonium lactate + 3% urea in W/O vehicle
Number of subjects: 20
Study 11803256 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ammonium lactate + 5% urea in W/O vehicle
Number of subjects: 20
Study 11803256 — intervention group
Group type: COMPARATOR
Intervention: drug‐free W/O vehicle
Number of subjects: 20
Study 10332446 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral paroxetine as needed 3 to 4 hours before planned intercourse (Study 1)
Number of subjects: 68
Study 10332446 — intervention group
Group type: COMPARATOR
Intervention: Placebo as needed (Study 1)
Number of subjects: 68
Study 10332446 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg paroxetine daily for 3 weeks and then 20 mg paroxetine as needed for 4 weeks (Study 2)
Number of subjects: 68
Study 10332446 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 3 weeks and then placebo as needed for 4 weeks (Study 2)
Number of subjects: 68
Study 10332446 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily and placebo as needed (Study 2)
Number of subjects: 68
Study 8750371 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 U/kg ardeparin
Number of subjects: 18
Study 8750371 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 U/kg ardeparin
Number of subjects: 18
Study 8750371 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U/kg ardeparin
Number of subjects: 18
Study 8750371 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ardeparin
Number of subjects: 18
Study 2025191 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloroplasty
Number of subjects: 24
Study 2025191 — intervention group
Group type: COMPARATOR
Intervention: No pyloroplasty
Number of subjects: 24
Study 6608885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitized with D. farinae
Number of subjects: 65
Study 6608885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitized with house dust (HD)
Number of subjects: 65
Study 6608885 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-treated patients
Number of subjects: 65
Study 6608885 — intervention group
Group type: COMPARATOR
Intervention: HD-treated patients
Number of subjects: 65
Study 30337060 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended LND
Number of subjects: 401
Study 30337060 — intervention group
Group type: COMPARATOR
Intervention: Limited LND
Number of subjects: 401
Study 29742189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrafol® Women's Capsules (active treatment)
Number of subjects: 40
Study 29742189 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 40
Study 26875743 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic lamotrigine product 1
Number of subjects: 35
Study 26875743 — intervention group
Group type: COMPARATOR
Intervention: Generic lamotrigine product 2
Number of subjects: 35
Study 25027424 — intervention group
Group type: EXPERIMENTAL
Intervention: Norvancomycin and heparin saline mixture
Number of subjects: 116
Study 25027424 — intervention group
Group type: COMPARATOR
Intervention: Heparin saline
Number of subjects: 116
Study 22318947 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg/day with a 36-h interval)
Number of subjects: 14
Study 22318947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20558919 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of LAM plus ADV combination therapy
Number of subjects: 29
Study 20558919 — intervention group
Group type: COMPARATOR
Intervention: Overlap/switch to adefovir dipivoxil (ADV) monotherapy
Number of subjects: 29
Study 20558919 — intervention group
Group type: COMPARATOR
Intervention: Overlap/switch to ADV monotherapy
Number of subjects: 29
Study 21418991 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐11 injection
Number of subjects: 48
Study 21418991 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 16282505 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking poles during 20-minute aerobic exercise for 8 weeks
Number of subjects: 12
Study 16282505 — intervention group
Group type: COMPARATOR
Intervention: No walking poles during 20-minute aerobic exercise for 8 weeks (Control)
Number of subjects: 12
Study 12110838 — intervention group
Group type: EXPERIMENTAL
Intervention: Venom immunotherapy (VIT)
Number of subjects: 74
Study 12110838 — intervention group
Group type: COMPARATOR
Intervention: EpiPen
Number of subjects: 74
Study 9542482 — intervention group
Group type: EXPERIMENTAL
Intervention: DMP 728 at doses of 0.05 to 0.9 mg
Number of subjects: 0
Study 9542482 — intervention group
Group type: EXPERIMENTAL
Intervention: DMP 728 at doses up to 0.6 mg
Number of subjects: 0
Study 9542482 — intervention group
Group type: EXPERIMENTAL
Intervention: DMP 728 at 0.9 mg
Number of subjects: 0
Study 9542482 — intervention group
Group type: EXPERIMENTAL
Intervention: DMP 728 at doses of 1.5 mg to 3.9 mg
Number of subjects: 0
Study 9542482 — intervention group
Group type: EXPERIMENTAL
Intervention: DMP 728 (all dose groups)
Number of subjects: 0
Study 9542482 — intervention group
Group type: EXPERIMENTAL
Intervention: DMP 728 (all doses)
Number of subjects: 0
Study 15374302 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Aramexe retard
Number of subjects: 18
Study 15374302 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Hydergine
Number of subjects: 18
Study 15374302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3391873 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid for 10 days
Number of subjects: 100
Study 3391873 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (ES) 500 mg tid for 10 days
Number of subjects: 100
Study 31755220 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combination (entecavir plus Peg‐interferon [IFN]α‐2a co‐administration during year 1)
Number of subjects: 447
Study 31755220 — intervention group
Group type: EXPERIMENTAL
Intervention: Late combination (addition of Peg‐IFNα‐2a for 48 weeks after 1 year of entecavir)
Number of subjects: 447
Study 31755220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue (NA) monotherapy
Number of subjects: 447
Study 31755220 — intervention group
Group type: COMPARATOR
Intervention: Non-antiviral treatment
Number of subjects: 447
Study 29633918 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel device for preoperative skin preparation
Number of subjects: 0
Study 29633918 — intervention group
Group type: COMPARATOR
Intervention: Current techniques of skin preparation
Number of subjects: 0
Study 27506926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hs‐TnT) reporting
Number of subjects: 1937
Study 27506926 — intervention group
Group type: COMPARATOR
Intervention: Standard reporting (std‐report)
Number of subjects: 1937
Study 27506926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hs‐TnT) reporting among patients with troponin levels <30 ng/L
Number of subjects: 1937
Study 27506926 — intervention group
Group type: COMPARATOR
Intervention: Standard reporting (std‐report) among patients with troponin levels <30 ng/L
Number of subjects: 1937
Study 25149556 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond blade (Group 2, 33 eyes)
Number of subjects: 70
Study 25149556 — intervention group
Group type: COMPARATOR
Intervention: Metal blade (Group 1, 37 eyes)
Number of subjects: 70
Study 25149556 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 23657308 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine (24 g/day)
Number of subjects: 46
Study 23657308 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine, 25 g/day)
Number of subjects: 46
Study 20734845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Mallampati test, Patila test, and ULBT test
Number of subjects: 0
Study 20734845 — intervention group
Group type: COMPARATOR
Intervention: Macintosh and Truview laryngoscopes
Number of subjects: 0
Study 20734845 — intervention group
Group type: COMPARATOR
Intervention: Other criteria of DTI
Number of subjects: 0
Study 19006471 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g P‐OM3 plus 40 mg rosuvastatin
Number of subjects: 48
Study 19006471 — intervention group
Group type: COMPARATOR
Intervention: 40 mg rosuvastatin alone
Number of subjects: 48
Study 16015260 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E co-supplementation with multi-drug therapy (MDT)
Number of subjects: 0
Study 16015260 — intervention group
Group type: COMPARATOR
Intervention: Multi-drug therapy (MDT)
Number of subjects: 0
Study 16015260 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated leprosy patients)
Number of subjects: 0
Study 12970290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta‐estradiol 2 mg combined with trimegestone 0.5 mg (E(2)+T)
Number of subjects: 60
Study 12970290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta‐estradiol 2 mg combined with dydrogesterone 10 mg (E(2)+D)
Number of subjects: 60
Study 12970290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10803797 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0
Study 10803797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8658325 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic extraperitoneal herniorrhaphy
Number of subjects: 0
Study 8658325 — intervention group
Group type: COMPARATOR
Intervention: Open repair (Shouldice hernioplasty)
Number of subjects: 0
Study 1387369 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg twice daily for 12 months)
Number of subjects: 23
Study 1387369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6465808 — intervention group
Group type: EXPERIMENTAL
Intervention: V-Y pushback
Number of subjects: 62
Study 6465808 — intervention group
Group type: COMPARATOR
Intervention: Langenbeck
Number of subjects: 62
Study 6465808 — intervention group
Group type: EXPERIMENTAL
Intervention: Langenbeck with pharyngeal flap
Number of subjects: 62
Study 30776296 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF (130 μg daily subcutaneous injections for a maximum of 9 weeks)
Number of subjects: 150
Study 30776296 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearing injections for a maximum of 9 weeks)
Number of subjects: 150
Study 30776296 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 150
Study 30776296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 29487948 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-psycho-social intervention
Number of subjects: 34
Study 29487948 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 34
Study 27050241 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity resistance training (HVRT) with 2 sessions per week in addition to regular soccer training (5 sessions per week)
Number of subjects: 24
Study 27050241 — intervention group
Group type: COMPARATOR
Intervention: Regular soccer training (5 sessions per week)
Number of subjects: 24
Study 25068301 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reporting of symptoms (experimental group)
Number of subjects: 41
Study 25068301 — intervention group
Group type: COMPARATOR
Intervention: Traditional interview method (control group)
Number of subjects: 41
Study 22436542 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise program
Number of subjects: 60
Study 22436542 — intervention group
Group type: COMPARATOR
Intervention: Standard medical advice from the attending physician (Control Group)
Number of subjects: 60
Study 20608875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from patients with pneumococcal meningitis
Number of subjects: 30
Study 20608875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from nonsurvivors (n = 9)
Number of subjects: 30
Study 20608875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from survivors (n = 11)
Number of subjects: 30
Study 20608875 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) from control subjects (n = 10)
Number of subjects: 30
Study 17909402 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 unit of packed red cells (PRC)
Number of subjects: 10
Study 17909402 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 units of packed red cells (PRC)
Number of subjects: 10
Study 16050428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen patches (100 microg per day)
Number of subjects: 27
Study 16050428 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 12585215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-small-particle-hybrid composite Point 4 with dentin adhesive OptiBond Solo Plus
Number of subjects: 73
Study 12585215 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist-bonding technique
Number of subjects: 73
Study 9649907 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal longitudinal relaxation velocity (RVm) measured in patients with AMI
Number of subjects: 22
Study 9649907 — intervention group
Group type: COMPARATOR
Intervention: Maximal longitudinal relaxation velocity (RVm) measured in healthy control subjects
Number of subjects: 22
Study 7661171 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 26
Study 7661171 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms
Number of subjects: 26
Study 7661171 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg
Number of subjects: 26
Study 2484789 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatment of 8 Gy
Number of subjects: 29
Study 2484789 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation of 24 Gy in six fractions over two to three weeks
Number of subjects: 29
Study 2484789 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation of 24 Gy in six fractions
Number of subjects: 29
Study 793780 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ketoprofen per day
Number of subjects: 30
Study 793780 — intervention group
Group type: COMPARATOR
Intervention: 150 mg indomethacin per day
Number of subjects: 30
Study 31717901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplementation (twice-a-day)
Number of subjects: 180
Study 31717901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 28333707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 48
Study 28333707 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 48
Study 28333707 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 48
Study 28333707 — intervention group
Group type: COMPARATOR
Intervention: Saline Control
Number of subjects: 48
Study 25933246 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 combined with cisplatin (SC)
Number of subjects: 72
Study 25933246 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone (C)
Number of subjects: 72
Study 24149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utility Score (HUS) > 0
Number of subjects: 2569
Study 24149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utility Score (HUS) < 0
Number of subjects: 2569
Study 24149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy responders
Number of subjects: 2569
Study 24149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with modified Rankin Scale
Number of subjects: 2569
Study 24149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with Barthel index
Number of subjects: 2569
Study 24149005 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with Zung depression score
Number of subjects: 2569